Get it on Google Play

Humacyte Phase 3 trial data to be presented at ASN Kidney Week

October 12, 2026 8:00 AM EDT Send to a Friend
Humacyte, Inc. (Nasdaq: HUMA) announced that interim results from its V012 Phase 3 clinical trial have been accepted for a ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login